Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.8% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in gene editing technologies, operating in a sector with considerable growth opportunities due to the potential for genetic disease treatment.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.8% on Jan 22, 2026 15:05

• NTLA saw a notable bullish trend today, potentially influenced by several key factors:
• A recent surge in the company's stock price and increased attention from ARK Investment and the J.P. Morgan Healthcare Conference have attracted investor interest.
• Varied signals on valuation, including indications of both undervaluation based on a DCF model and potential overvaluation suggested by a high P/S ratio, may have led to market volatility and trading possibilities.
• The generally optimistic outlook for the gene editing industry, underscored by anticipated market expansion and transformative prospects for genetic disease treatment, may have also bolstered NTLA's bullish movement.
• Investors weighing the risks associated with stock volatility, clinical trial results, and regulatory challenges within the gene editing market could have also contributed to NTLA's market performance.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Decoding the Gene Editing Sector and Focusing on Progress and Investment Perspectives of Three Leading Companies

The gene editing market, projected to reach $30.8 billion by 2032, holds revolutionary potential for treating genetic diseases. This article highlights three leading companies—Intellia Therapeutics, CRISPR Therapeutics, and Beam Therapeutics—showcasing their progress with clinical trials and regulatory approvals. While the sector offers significant long-term returns, investors face high risks including stock volatility, clinical trial failures, and regulatory hurdles.

https://nai500.com/blog/2026/01/decoding-the-gene-editing-sector-and-focusing-on-progress-and-investment-perspectives-of-three-leading-companies/

Is Intellia Therapeutics (NTLA) Pricing Make Sense After Sharp Rebound And DCF Upside Signals

This article analyzes Intellia Therapeutics (NTLA) post a recent sharp rebound, evaluating its current valuation using Discounted Cash Flow (DCF) and Price-to-Sales (P/S) models. While the DCF model suggests the stock is significantly undervalued by 94.5% at an intrinsic value of $234 per share compared to its current price of $12.83, the P/S ratio indicates it is overvalued relative to industry and peer averages. The article highlights that for rapidly growing biotech companies, P/S can be more informative than P/E, but also introduces the "Narratives" approach for investors to connect their beliefs about a company's prospects with financial forecasts.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/is-intellia-therapeutics-ntla-pricing-make-sense-after-sharp

Assessing Intellia Therapeutics (NTLA) Valuation After Recent Share Price Rebound and Conflicting Fair Value Signals

Intellia Therapeutics (NTLA) has experienced a recent share price rebound after a period of decline, showing a 35.4% one-month return. Despite this, the company, currently trading at US$12.50, is still loss-making. Conflicting valuation signals exist, with one narrative suggesting a 43.9% undervaluation with a fair value of US$22.27, while a DCF model indicates it's extremely cheap with a fair value of US$233.98.

https://finance.yahoo.com/news/assessing-intellia-therapeutics-ntla-valuation-042814731.html

A Look At Intellia Therapeutics (NTLA) Valuation After ARK’s Added Stake And J.P. Morgan Conference Spotlight

Intellia Therapeutics (NTLA) is gaining attention after ARK Investment increased its stake and the company prepares for the J.P. Morgan Healthcare Conference. While a narrative model suggests the stock is significantly undervalued with a fair value of $22.27, based on its promising clinical pipeline and favorable market trends, a simple P/S ratio analysis indicates it is expensive compared to its peers. Investors are encouraged to consider both perspectives and associated risks like trial safety and potential dilution.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-arks-ad/amp

A Look At Intellia Therapeutics (NTLA) Valuation After ARK’s Added Stake And J.P. Morgan Conference Spotlight

Intellia Therapeutics (NTLA) is drawing renewed interest following ARK Investment's increased stake and its upcoming presentation at the J.P. Morgan Healthcare Conference. While the stock has seen recent gains after a volatile period, Simply Wall St's analysis suggests NTLA is undervalued with a fair value of $22.27, primarily driven by the potential of its clinical pipeline and market expansion. However, a high P/S ratio indicates the stock is expensive, highlighting conflicting valuation signals.

https://www.sahmcapital.com/news/content/a-look-at-intellia-therapeutics-ntla-valuation-after-arks-added-stake-and-jp-morgan-conference-spotlight-2026-01-16

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 5.4% Today

Internet Computer ($ICP) Crypto Forecast: Down 5.0% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 7.7% Today

Mobileye Global ($MBLY) Stock Forecast: Down 7.0% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 5.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 10.7% Today

Intel Corporation ($INTC) Stock Forecast: Down 17.6% Today

Live Nation Entertainment Inc. ($LYV) Stock Forecast: Up 4.9% Today

Sonos Inc. ($SONO) Stock Forecast: Down 5.2% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 8.0% Today

Intellia Therapeutics, Inc. Price History

06.00.2026 - NTLA Stock was up 6.3%

• The market sentiment towards NTLA has been negative due to a regulatory setback and FDA clinical hold on its main pipeline candidate, as well as mixed Q3 results.
• NTLA experienced a significant bullish movement today because of the inducement grants introduced by the company to recruit new talent.
• This action underscores Intellia's dedication to its goals and likely boosted investor confidence in the company's future, despite recent challenges.

20.00.2026 - NTLA Stock was up 5.0%

• Intellia Therapeutics (NTLA) witnessed a significant bullish movement recently, possibly influenced by ARK Invest's continuous buying and increased position in the company.
• Despite conflicting valuations, investor confidence in Intellia's clinical pipeline and overall market trends has supported the stock's upward trajectory.
• The company's recovery from a previous decline, ongoing progress in clinical trials, and favorable analyst recommendations have all reinforced investor confidence and contributed to the positive market movement.
• ARK's consistent investment in Intellia, despite past stock fluctuations, reflects strong confidence in the company's future prospects and the effectiveness of its CRISPR-based therapy approach.

13.00.2026 - NTLA Stock was up 9.3%

• The bullish movement in NTLA stock can be attributed to positive analyst sentiments and Buy ratings from firms like TD Cowen, UBS, and Barclays, indicating confidence in the company's future performance.
• Despite recent setbacks such as the FDA clinical hold on its lead gene editing trial due to safety concerns, investors may be optimistic about the company's ability to address these issues and move forward with its clinical trials and regulatory plans.
• The upcoming presentation at the J.P. Morgan Healthcare Conference could also be fueling investor optimism, as it provides a platform for the company to showcase its developments and potentially attract more interest from the market.
• The conflicting views on NTLA's valuation, with some considering it undervalued while others pointing out its high Price-to-Sales ratio, highlight the complexity of assessing the stock's true worth and the importance of considering various factors before making investment decisions.

17.11.2025 - NTLA Stock was up 5.3%

• Marex Group plc acquired a noteworthy stake in NTLA in Q2, reflecting increasing investor confidence in the company's potential and future growth.
• Intellia Therapeutics exceeded Q3 earnings expectations, surpassing EPS estimates by $0.10, likely contributing to the positive market sentiment.
• Despite currently facing a class action lawsuit concerning securities fraud linked to the NTLA-3001 study, investors appear positive about the company's ability to tackle these legal challenges and concentrate on its innovative treatments.

21.00.2026 - NTLA Stock was up 15.0%

• Conflicting valuation signals are evident for the stock, as with a DCF model suggesting undervaluation but a P/S ratio indicating overvaluation compared to industry peers.
• Renewed interest in the stock has been sparked by ARK Investment's increased stake and the upcoming J.P. Morgan Healthcare Conference.
• ARK Invest, led by Cathie Wood, has shown confidence in the company's future prospects by acquiring NTLA shares for three consecutive days.
• Despite positive clinical trial progress and recent gains, the stock's valuation remains a matter of debate among investors and analysts.

08.00.2026 - NTLA Stock was up 5.1%

• The surge in NTLA's stock price may be linked to notable insider purchasing activity by Director Fred Cohen, who acquired 150,000 shares of the company's common stock. This insider buy could have boosted market confidence in the company's future outlook.
• Contrasting Cohen's buying behavior with other insider transactions, which lean towards more sells than buys, might have indicated to investors that the director is optimistic about the company's long-term potential.
• Furthermore, anticipation surrounding the company's participation in the 44th Annual J.P. Morgan Healthcare Conference, where Intellia Therapeutics will discuss its CRISPR-based therapies, could have generated positive investor sentiment and contributed to the stock's bullish movement.
• Overall, a combination of insider buying activities, positive advancements in clinical trials, and involvement in a reputable healthcare conference likely fueled investor optimism, driving the upward momentum in NTLA's stock price.

12.00.2026 - NTLA Stock was down 3.1%

• The recent bearish movement in NTLA could be attributed to the FDA clinical hold on its lead gene editing trial following safety concerns like a patient death and liver enzyme elevations, leading to uncertainty among investors.
• Despite being considered undervalued by some analysts, the high Price-to-Sales (P/S) ratio of 20.4x compared to the industry average of 12.1x raises questions about its true valuation, potentially causing bearish sentiment.
• The conflicting views from different valuation methods and the upcoming presentation at the J.P. Morgan Healthcare Conference might have added to the volatility and uncertainty surrounding NTLA's future prospects, influencing the bearish market movement.
• The insider buying activity by Fred Cohen, acquiring a significant number of shares, could indicate his confidence in the company's long-term potential, contrasting with the broader market sentiment and potentially signaling a divergence in perspectives among investors.

22.00.2026 - NTLA Stock was up 5.8%

• NTLA saw a notable bullish trend today, potentially influenced by several key factors:
• A recent surge in the company's stock price and increased attention from ARK Investment and the J.P. Morgan Healthcare Conference have attracted investor interest.
• Varied signals on valuation, including indications of both undervaluation based on a DCF model and potential overvaluation suggested by a high P/S ratio, may have led to market volatility and trading possibilities.
• The generally optimistic outlook for the gene editing industry, underscored by anticipated market expansion and transformative prospects for genetic disease treatment, may have also bolstered NTLA's bullish movement.
• Investors weighing the risks associated with stock volatility, clinical trial results, and regulatory challenges within the gene editing market could have also contributed to NTLA's market performance.

28.10.2025 - NTLA Stock was up 5.8%

• Intellia's bullish movement could be attributed to the positive advancements in its in vivo pipeline, particularly the progress in the HAELO study with lonvo-z.
• The comparison with a rival company might have sparked investor interest and confidence in Intellia's potential for long-term growth.
• The anticipation of mid-2026 data and a potential filing in the same year could have fueled optimism among investors, leading to the bullish market movement for NTLA today.

16.00.2026 - NTLA Stock was up 6.7%

• Continued buying activity of Intellia Therapeutics (NTLA) stock by a prominent investor totaling approximately $682,000 has boosted investor confidence and pushed the stock price up.
• Despite recent challenges such as regulatory issues and a decline in stock price, Intellia's recovery and positive clinical trial advances have led to a 32% increase in stock value year-to-date, reflecting optimism among investors.
• Initial concerns regarding brokerage ratings and insider selling have been overshadowed by a recent purchasing spree by a notable investor and the company's strong Q3 earnings performance.
• The market's positive response to the ongoing investor confidence and growth potential of Intellia Therapeutics, despite recent obstacles, indicates a bullish trend in the market.

15.00.2026 - NTLA Stock was down 5.0%

• Despite facing safety concerns leading to the halting of Intellia Therapeutics' MAGNITUDE ATTR-CM trial by the FDA, the stock saw a notable surge of 20.7%. This unexpected positive movement could be linked to various factors:
• The market may be responding favorably to the ongoing Phase 3 ionvo-z trial for hereditary angioedema, which is currently fully enrolled and expected to yield results in mid-2026, potentially driving growth.
• The increased acquisition of 92,485 NTLA shares by SG Americas Securities LLC possibly boosted investor confidence, despite recent insider selling activities.
• Analysts expressing optimism about Intellia Therapeutics, with TD Cowen assigning a Buy rating, could have also played a role in the stock's upward trajectory, standing out amidst the general market pessimism.

28.10.2025 - NTLA Stock was up 5.4%

• The bullish movement in NTLA could be attributed to the company's recent positive developments in its gene editing therapies, outshining its competitor BEAM.
• Investors might be favoring NTLA over BEAM due to its specific pipeline advancements and promising study results, leading to increased confidence in NTLA's potential for growth.
• This market movement suggests that NTLA's strategic positioning and progress in the gene editing sector are resonating well with investors, driving up the stock price significantly.